Programs

Optimizing Outcomes in Newly Diagnosed Multiple Myeloma: Integrating Anti-CD38 Monoclonal Antibody Therapy Into Clinical Practice

Did you miss the latest updates on multiple myeloma presented at ASH 2021? Join Dr Faith Davies and Dr Nina Shah as they review late-breaking data on approved and emerging therapies for newly diagnosed multiple myeloma!

https://learning.freecme.com/a/38663PA6uG2J

 

Itching for a CSU Cure: The Shift From Symptom Relief to Curative Therapies – An Older African American Adult Male With Widespread, Persistent Pruritus

Join Chesahna Kindred, MD, MBA, FAAD, and Jonathan A. Bernstein, MD, as they discuss missed opportunities for the management and assessment of chronic spontaneous urticaria (CSU) in this interactive learning experience that uniquely mirrors what you may encounter in clinical practice. The activity will present you with a CSU patient with skin of color and challenge your clinical decision-making skills.

https://realcme.realcme.com/learner/course/2855

 

 

Itching for a CSU Cure: The Shift From Symptom Relief to Curative Therapies – A Caucasian Adult Female With Recurrent, Uncontrolled Angioedema and Urticaria

Join Chesahna Kindred, MD, MBA, FAAD, and Jonathan A. Bernstein, MD, as they discuss missed opportunities for the diagnosis, management, and assessment of chronic spontaneous urticaria (CSU) in this interactive learning experience that uniquely mirrors what you may encounter in clinical practice. The activity will present you with a CSU patient receiving suboptimal care and challenge your clinical decision-making skills.

https://realcme.realcme.com/learner/course/2854

Strategies for PD-L1 Testing and Targeted Therapy With Immune Checkpoint Inhibitors for NSCLC

Join Dr Hossein Borghaei and Dr Kurt Schalper in this personalized adaptive learning platform as they share insights into the role of PD-L1 testing to determine the best approach to ICI therapy, current efficacy and safety data for ICI therapies in NSCLC, and how to identify and mitigate immune-related adverse events (irAEs).

 

Click below to enter this activity:
https://spirelearning.realcme.com/learner/course/2828

The Evolving Landscape of Chronic Lymphocytic Leukemia: Selecting and Managing Targeted Therapy

In this educational activity, faculty members Nina Delaney Wagner-Johnston, MD, and Seema A. Bhat, MD, review current efficacy and safety data for targeted therapies approved for patients with treatment-naïve or relapsed/refractory (R/R) CLL, as well as emerging strategies for treatment. They evaluate clinical trial data, along with patient- and disease-related factors, that allow for the individualization of therapy selection and sequencing of therapy in first and second lines of therapy and beyond.

https://reachmd.com/programs/cme/evolving-landscape-chronic-lymphocytic-leukemia-selecting-and-managing-targeted-therapy/12643/